Current status of the FRIGG project
The FRIGG project ultimately aims to improve life quality for patients with chronic kidney disease (CKD). Here, Lene N. Nejsum and Rikke Nørregaard, who are heading the project together, provides a short status update of the FRIGG project.
“We aim pave the way for the development of new drugs and improved treatment of patients with chronic kidney disease” says Rikke Nørregaard and Lene N. Nejsum. Together they are heading the FRIGG project, where they use fresh human kidney tissue to model chronic kidney disease (CKD).
CKD is a growing cause of global mortality. Therefore, Lene and Rikke’s team is developing a new translational CKD model. In addition, they are identifying clinically-relevant biomarkers. Both of these tools will help researchers in the drug development process.
“In FRIGG we are using human kidney slices to model the early stages of human CKD development in order to identify both novel CKD biomarkers as well as therapeutic targets.” says Lene
“We have a close collaboration with our industry partners from Novo Nordisk, AstraZeneca and Nordic Bioscience. Together, we will evaluate the translatability of the model.” continues Rikke
Both Lene and Rikke are certain that the FRIGG project will generate new and useful knowledge about the CKD. We are certain that the combination of kidney slices with advanced OMICs platforms will provide unprecedented insight into the pathophysiological processes that drive CKD.